Immunophenotyping of Peripheral T Cells After T Cell Depletion With Alemtuzumab

Phase 4 Terminated 52 enrolled Northwestern University American Society of Transplant Surgeons · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to check the T and B cells of the immune system in 50 newly transplanted patients whom have received a kidney (50 recipients and 50 donors totaling 100 anticipated participants). This will be done to see how the Standard of Care (SOC) anti-rejection medication, Alemtuzumab (Campath 1-H®) affects these cells- Campath 1-H® reduces the number of T cells produced by one's body.

Timeline

Start: 2006-02
Primary completion: 2009-04
Completion: 2009-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	30 mg	Intravenous

Indications

No indication recorded.